We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
- Authors
Grundy, Scott M; Vega, Gloria Lena; McGovern, Mark E; Tulloch, Brian R; Kendall, David M; Fitz-Patrick, David; Ganda, Om P; Rosenson, Robert S; Buse, John B; Robertson, David D; Sheehan, John P; Diabetes Multicenter Research Group
- Abstract
Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels. Niacin reduces concentrations of triglyceride-rich and small low-density lipoprotein particles while increasing high-density lipoprotein cholesterol levels. It also lowers levels of free fatty acids and lipoprotein(a). However, the use of niacin in patients with diabetes has been discouraged because high doses can worsen glycemic control. We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia.
- Publication
Archives of internal medicine, 2002, Vol 162, Issue 14, p1568
- ISSN
0003-9926
- Publication type
Journal Article
- DOI
10.1001/archinte.162.14.1568